The European Stroke Organisation Conference (ESOC) 2017 took place this week from 16-18 May in Prague, Czech Republic. The third day of ESOC saw some exciting late breaking clinical trials.
The European Stroke Organisation Conference (ESOC) 2018 is currently on from 16-18 May in Gothenburg, Sweden. The first day of ESOC included some truly inspiring scientific sessions, including the WAKE-UP trial, RIGHT-2 trial and CROMIS-2 trials.
Published online first in the journal Neurology, a new study suggests that people with AF who have an ICH due to their medication have similar outcomes whether they're on a NOAC or a vitamin K antagonist drug.
The European Stroke Organisation Conference (ESOC) 2018 took place between 16-18 May in Gothenburg, Sweden. The third day of ESOC featured new research which identified how to improve stroke care worldwide – from simple measures in low to middle-income countries, through to refinement of advanced techniques for acute and preventative stroke treatments.
Currently, a drug called alteplase is used in thrombolysis, but the researchers think that another drug, called tenecteplase, may be more effective than alteplase.
This study is investigating whether colchicine, a medication used to treat gout, could help to stop people who have previously had a stroke or TIA from having further strokes.
Published in the journal, Lancet Neurology, a new study suggests that understanding stroke severity, as well as time to treatment, is key to delivering effective and safe thrombolysis treatment.
Published in the journal Stroke, a new study suggests that a drug commonly used to treat rheumatoid arthritis may help reduce harmful inflammation in the brain after stroke. The study was funded by the Stroke Association.